.gif)
Clore Laboratory: Publications
Diabetes, Obesity and Metabolic Research
Publications
Peer Reviewed Publications
Ngala RA, O'Dowd J, Wang SJ, Stocker C, Cawthorne MA, Arch JRS. β2-Adrenoceptors and non-β-adrenoceptors mediate effects of BRL37344 and clenbuterol on glucose uptake in soleus muscle: studies using knockout mice. Br J Pharmacol 2009 Dec; 158(7):1676–82. doi:10.1111/j.1476-5381.2009.00472.x
Mracek T, Gao D, Tzanavari T, Bao Y, Xiao X, Stocker CJ, Trayhurn P, Bing C. Downregulation of zinc-α2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-α in adipocytes. J Endocrinol 2009 Nov 27, e-pub ahead of print. doi: 10.1677/JOE-09-0299
Cornick CL, Strongitharm BH, Sassano G, Rawlins C, Mayes AE, Joseph AN, O’Dowd J, Stocker C, Wargent E, Cawthorne MA, Brown AL, Arch JRS. Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice. J Nutr Biochem. 2009, Oct 20(10):806-815, e-pub ahead of print 14 October 2008. doi:10.1016/j.jnutbio.2008.07.010
Stocker CJ, Cawthorne MA. The influence of leptin on early life programming of obesity.
Trends Biotechnol. 2008 26(10):545–551. e-pub ahead of print 14 August 2008. doi:10.1016/j.tibtech.2008.06.004
Arch JRS. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β3-adrenoceptor agonists. Naunyn-Schmied Arch Pharmacol. 2008 Aug;378(2):225–240. e-pub 9 July 2008. doi:10.1007/s00210-008-0271-1
Ngala RA, O’Dowd J, Wang SJ, Agarwal A, Stocker C, Cawthorne MA, Arch JRS. Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and β2-adrenoceptor mechanisms. Br J Pharmacol. 2008 Oct;155(3): 395–406;e-pub 16 June 2008. doi:10.1038/bjp.2008.244
Fyfe MCT, White JR, Taylor A, Chatfield R, Wargent E, Printz RL, Sulpice T, McCormack JG, Procter MJ, Reynet C, Widdowson PS, Wong-Kai-In P. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia. 2007 Jun;50(6):1277–1287. e-pub 6 Apr 2007. doi:10.1007/s00125-007-0646-8
Clapham JC, Arch JRS. Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes Metab. 2007 May;9(3):259–275.e-pub 26 May 2006 doi:10.1111/j.1463-1326.2006.00608.x
Schmid GM, Meda P, Caille D, Wargent E, O’Dowd J, Hochstrasser DF, Cawthorne MA, Sanchez J-C. Inhibition of insulin secretion by betagranin, a N-terminal chromogranin A fragment. J Biol Chem. 2007 Apr;282(7):12717–12724. e-pub 8 Feb 2007. doi:10.1074/jbc.M700788200
Cawthorne MA. Opportunities and challenges for the development of pharmacological therapies for obesity treatment. Obes Rev. 2007 Mar;8 (Suppl 1):131–136. doi:10.1111/j.1467-789X.2007.00332.x
Wang SJ, Cornick C, O’Dowd J, Cawthorne MA, Arch JRS. Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet. Lipids Health Dis. 2007, 6(2) doi:10.1186/1476-511X-6-2
Stocker CJ, Wargent E, O’Dowd J, Cornick C, Speakman JR, Arch JRS, Cawthorne MA. Prevention of diet-induced obesity and impaired glucose tolerance in rats following administration of leptin to their mothers. Am J Physiol Regul Integr Comp Physiol. 2007 292:R1810–R1818. First published 18 January 2007. doi:10.1152/ajpregu.00676.2006
Arch JRS. Comment on: ‘Schmidt MI, Duncan BB, Vigo A et al. (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia 49:2086-2096.’ Diabetologia. 2007 Jan;50(1):239–240. doi:10.1007/s00125-006-0523-x. Epub 10 Nov 2006
A.S. McLellan, T. Kealey and K. Langlands (2006). An E box in the exon 1 promoter regulates insulin-like growth factor-I expression in differentiating muscle cells. Am. J. Physiol. Cell Physiol. 291(2), C300–C307. Epub 2006 March 22; doi:10.1152/ajpcell.00345.2005
J.R.S. Arch, D. Hislop, S.J.Y. Wang and J.R. Speakman (2006). Some mathematical and technical issues in the measurement and interpretation of open-circuit indirect calorimetry in small animals. Int. J. Obes. 30, 1322–1331. Published online 27 June 2006; doi:10.1038/sj.ijo.0803280
S.J.Y. Wang, S. Birtles, J. de Schoolmeester, J. Swales, G. Moody, D. Hislop, J. O’Dowd, D.M. Smith, A.V. Turnbull and J.R.S. Arch (2006). Inhibition of 11β-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 49(6), 1333–1337. Published online 13 April 2006, ahead of print. doi:10.1007/s00125-006-0239-y
C.L. Yang, T. Kurczab, G. Down, T. Kealey and K. Langlands (2005). Gene expression profiling of the ageing rat vibrissa follicle. Br. J. Dermatol. 153(1), 22–28.
C.J. Stocker, J.R.S. Arch and M.A. Cawthorne (2005). Fetal origins of insulin resistance and obesity. Proc. Nutr. Soc. 64(2), 143–151 doi:10.1079/PNS2005417
E. Wargent, C. Stocker, P. Augstein, P. Heinke, A. Meyer, T. Hoffmann, A. Subramanian, M.V. Sennitt, H.-U. Demuth, J.R.S. Arch and M.A. Cawthorne (2005). Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obes. Metab., 7(2), 170–181. doi:10.1111/j.1463-1326.2004.00383.x
J.R.S. Arch (2005). Central regulation of energy balance: inputs, outputs and leptin resistance. Proc. Nutr. Soc. 64(1), 39–46. doi:10.1079/PNS2004407
E. Wargent, M.V. Sennitt, C. Stocker, A.E. Mayes, L. Brown, J. O’Dowd, S.J.Y. Wang, A.W.C. Einerhand, I. Mohede, J.R.S. Arch and M.A. Cawthorne (2005). Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Lipids Health Dis., 4, 3. Published 10 January 2005. doi:10.1186/1476-511X-4-3
J.R.S. Arch (2004). Do low-affinity states of β-adrenoceptors have roles in physiology and medicine? Br. J. Pharmacol. 143, 517–518.
N.J. Pearce, J.R. Arch, J.C. Clapham, M.P. Coghlan, S.L. Corcoran, C.A. Lister, A. Llano, G.B. Moore, G.J. Murphy, S.A. Smith, C.M. Taylor, J.W. Yates, A.D. Morrison, A.J. Harper, L. Roxbee-Cox, A. Abuin, E. Wargent and J.C. Holder (2004). Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3β on a muscle-specific promoter. Metabolism 53,1322-1330.
G.M. Schmid, V.Converset, N.Walter, M.V. Sennitt, K.-.Y Leung, H. Byers, M. Ward, D.F. Hochstrasser, M.A. Cawthorne and J.C. Sanchez (2004). Effect of high-fat diet on the expression of proteins in muscle, adipose tissues, and liver of C57Bl/6 mice. Proteomics 4, 2270-2282. Published online 21 June 2004.
C. Stocker, J. O'Dowd, N.M. Morton, E. Wargent, M.V. Sennitt, D. Hislop, S. Glund, J.R. Seckl, J.R.S. Arch and M.A. Cawthorne (2004). Modulation of susceptibility to weight gain and insulin resistance in low birthweight rats by treatment of their mothers with leptin during pregnancy and lactation. Int. J. Obes. Relat. Metab. Disord. 28, 129-136. Published online 14 October 2003.
J.C. Sanchez, V. Converset, A. Nolan, G. Schmid, S. Wang, M. Heller, M.V. Sennitt, D.F. Hochstrasser and M.A.Cawthorne (2003). Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. Proteomics 3,1500-1520.
S. Wang, A. Subramaniam, M.A. Cawthorne and J.C. Clapham (2003). Increased fatty acid oxidation in transgenic mice overexpressing UCP3 in skeletal muscle. Diabetes, Obes. Metab. 5, 295-301.
K.S. Echtay, T.C. Esteves, J.L. Pakay, M.B. Jekabsons, A.J. Lambert, M. Portero-Otin, R. Pamplona, A.J. Vidal-Puig, S. Wang, S.J. Roebuck and M.D. Brand (2003). A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling. EMBO J. 22, 4103-4110.
J.R.S. Arch (2002). Lessons in obesity from transgenic animals. J. Endocrinol. Invest. 25, 867-875.
J-C. Sanchez, V. Converset, A. Nolan, G. Schmid, S. Wang, M. Heller, M.V. Sennitt, D.F. Hochstrasser, and M.A. Cawthorne (2002). Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57Bl/6 lep/lep mice. Mol. Cell. Proteomics 1, 509-516.
D. Smart, A.C. Haynes, G. Williams and J.R.S. Arch (2002). Orexins and the treatment of obesity. Eur. J. Pharmacol. 440, 199-212.
J.R.S. Arch (2002). b3-Adrenoceptor agonists: potential, pitfalls and progress. Eur. J. Pharmacol. 440, 99-107.
S. Wang, M.A. Cawthorne and J.C. Clapham (2002). Enhanced diabetogenic effect of streptozotocin in mice overexpressing UCP-3 in skeletal muscle. Ann. N.Y. Acad. Sci. 967, 112-119.
A.C. Haynes, H. Chapman, C. Taylor, G.B. Moore, M.A. Cawthorne, M. Tadayyon, J.C. Clapham and J.R.S. Arch (2002). Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regulatory Peptides 104, 153-159.
X.J. Cai, H.L. Liu, M. Evans, J.C. Clapham, S. Wilson, J.R.S. Arch and G. Williams (2002). Orexins and feeding: special occasion or everyday occurrence? Regul. Pept. 104, 1-9.
V. Emilsson, J. O'Dowd, A.L. Nolan and M.A. Cawthorne (2001). Hexosamines and nutrient excess induce leptin production and leptin receptor activation in pancreatic islets and clonal beta-cells. Endocrinology 142, 4414-4419.
J-C. Sanchez, D. Chiappe, V. Converset, C. Hoogland, P-A. Binz, S. Paesano, R. D. Appel, S. Wang, M. Sennitt, A. Nolan, M. A. Cawthorne and D. F. Hochstrasser (2001). The mouse SWISS-2D PAGE database: a tool for proteomics study of diabetes and obesity. Proteomics 1, 136-163.
V. Emilsson, J. O'Dowd, S. Wang, Y-L. Liu, M. Sennitt, R. Heyman and M.A. Cawthorne (2000). The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 49, 1610-1615.
M.S. Islam, A. Sjoholm and V. Emilsson (2000). Fetal pancreatic islets express functional leptin receptors and leptin stimulates proliferation of fetal islet cells. Int. J. Obesity 24, 1246-1253.
M. Board, P. Doyle and M.A.Cawthorne (2000). BRL 37344, but not CGP 12177, stimulates fuel oxidation by soleus muscle in vitro. Eur. J. Pharmacol. 406, 33-40.
Y.-L. Liu, M.V. Sennitt, D.C. Hislop, D.L. Crombie, R.A. Heyman and M.A. Cawthorne (2000). Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats. Int. J. Obesity 24, 997-1004.
P.D. Chamberlain, K.H. Jennings, F. Paul, J. Cordell, A. Berry, S.D. Holmes, J. Park, J. Chambers, M.V. Sennitt, M.J. Stock, M.A. Cawthorne, P.W. Young and G.J. Murphy (1999). The tissue distribution of the human bβ-adrenoceptor studied using a monoclonal antibody: direct evidence of the b3-adrenoceptor in human adipose tissue, atrium and skeletal muscle. Int. J. Obesity 23, 1057-1065.
V. Emilsson, J.R.S. Arch, R.P. de Groot, C.A. Lister and M.A. Cawthorne (1999). Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett. 455, 170-174.
N.M. Morton, V. Emilsson, R.P. de Groot, A.L. Pallett and M.A. Cawthorne (1999). Leptin signalling in pancreatic islets and clonal insulin-secreting cells. J. Mol. Endocrinol. 22, 173-184.
N.M. Morton, R.P. de Groot, M.A. Cawthorne and V. Emilsson (1999). Interleukin-1b activates a short STAT-3 isoform in clonal insulin-secreting cells. FEBS Lett., 442, 57-60.
V. Emilsson, R.J. Summers, S. Hamilton, Y-L. Liu and M.A. Cawthorne (1998). The effects of the b3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression. Biochem. Biophys. Res. Commun. 252, 450-454
N.M. Morton, V. Emilsson, Y.-L. Liu and M.A. Cawthorne (1998). Leptin action in intestinal cells. J. Biol. Chem. 273, 26194-26201.
M.A. Cawthorne, N.M. Morton, A.L. Pallett, Y-L. Liu and V. Emilsson (1998). Peripheral metabolic actions of leptin. Proc. Nutr. Soc. 57, 449-453.
M.V. Sennitt, A.J. Kaumann, P. Molenaar, L.J. Beeley, P.W. Young, J. Kelly, H. Chapman, S.M. Henson, J.M. Berge, D.K. Dean, N.R. Kotecha, H.K.A. Morgan, H.K. Rami, R.W. Ward, M. Thompson, S. Wilson, S.A. Smith, M.A. Cawthorne, M.J. Stock and J.R.S. Arch (1998). The contribution of classical ( b1/2 ) and atypical b-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel b3-adrenoceptor agonists of different selectivities. J. Pharm. Exp. Therap. 285, 1084-1095.
Md. S. Islam, N.M. Morton, A. Hansson and V. Emilsson (1997). Rat insulinoma-derived pancreatic b-cells express a functional leptin receptor that mediates a proliferative response. Biochem. Biophys. Res. Commun. 238, 851-855.
A.L. Pallett, N.M. Morton, M.A. Cawthorne and V. Emilsson (1997). Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. Biochem. Biophys. Res. Commun. 238, 267-270.
Y.L. Liu, V. Emilsson and M.A. Cawthorne (1997). Leptin inhibits glycogen synthesis in the isolated soleus muscle of obese (ob/ob) mice. FEBS Lett. 411, 351-355.
V. Emilsson, Y.L. Liu, M.A. Cawthorne, N.M. Morton and M. Davenport (1997). Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 46, 313-316.
S.L. Pearson, M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B.T. Moore, S.A. Smith and M. Tadayyon (1996). The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPARg and aP2 in adipose tissue of high fat fed rats. Biochem. Biophys. Res. Commun. 229, 752-757.
C. Deng, A. Paoloni-Giacobino, F. Kuehne, O. Boss, J-P. Revelli, M. Moinat, M.A. Cawthorne, P. Muzzin and J-P Giacobino (1996). Respective degree of expression of b1 , b2 and b3 -adrenoceptors in human brown and white adipose tissue. Br. J. Pharmacol. 118, 929-934. L.J. Beeley and M.A. Cawthorne (1996). Lean Prospects. Chem. Britain, May 31-34.
Y-L. Liu, M.A. Cawthorne and M.J. Stock (1996). Biphasic effects of the
b-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle. Br. J. Pharmacol. 117, 1355-1361.
Abstracts
The full reference is:
C. Stocker, E. Wargent, J. O'Dowd, R. Ngala, D. Carling, J. Arch and M. Cawthorne (2007). Patterns of postnatal growth impact on the early life programming of energy balance. Early Hum. Dev. 83, Suppl 1, S113, Abs P1-109.
M.A. Cawthorne, E. Wargent, M. Zaibi, C. Stott and S. Wright (2007). The CB-1 antagonist delta-9-tetrahydrocannabivarin (THCV) has anti-obesity activity in dietary-induced obese (DIO) mice. ‘17 Annual Symposium on the Cannabinoids’, Burlington, Vermont, International Cannabinoid Research Society, page 141.
C. Stocker, E. Wargent, K. Smith, J. O’Dowd, J. Arch and M. Cawthorne (2006). Early life programming of appetite by maternal leptin administration. Obes. Rev. 7, Suppl 2, 153, PO0132.
C. Stocker, E. Wargent, J. O'Dowd, D. Carling, J. Arch and M. Cawthorne (2006). Leptin supplementation in early life programmes muscle metabolism. Obes. Rev. 7, Suppl 2, 43, OP0015.
S. Wang, C. Cornick, J. O’Dowd and J. Arch (2005). Energy balance and glucose homeostasis in DGAT-1 homozygous and heterozygous knockout mice on chow and high fat diets. Obes. Res. 13, Suppl 1, A52, 202-P.
M. Cawthorne, E. Wargent, J. O’Dowd, D. Hislop, J. Arch and C. Stocker (2005). Pharmacologic treatment of dams programs offspring to resist diet-induced obesity. Obes. Res. 13, Suppl 1, A1, 2-OR.
J.R.S. Arch , S.J.Y. Wang, S. Birtles, D.M. Smith and A. Turnbull (2005). Effects of an inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 inhibitor on energy balance and glucose homeostasis in diet-induced obesity. Diabetologia 48, Suppl. 1, A238, Abs. 650.
J.F. O’Dowd, C. Cornick, C.J. Stocker, S.J.Y. Wang, M.A. Cawthorne and J.R S. Arch (2005). Identification of preprodynorphin as a pancreatic gene associated with increased susceptibility to diabetes. Diabetologia 48, Suppl. 1, A158, Abs. 425.
M.C.T. Fyfe, M.A. Cawthorne, M.V. Sennitt and R.L. Printz (2005). Antihyperglycemic effects of novel long- and short-acting glucokinase activators (PSN105 and PSN010) in diabetic animals. Diabetes 54, Suppl. 1, A129, Abs. 522-P.
P. Wong-Kai-In, M.A. Cawthorne, E. Wargent and G. Thomas (2005). PSN357, a novel glycogen phosphorylase inhibitor with anti-hyperglycemic efficacy in rodent models of diabetes. Diabetes 54, Suppl. 1, A140, Abs. 567-P.
J.R.S Arch, E. Wargent, M.V. Sennitt, C. Stocker, A.E.Mayes, L. Brown, J. O’Dowd, S. Wang, A.W.C. Einerhand, I. Mohede and M.A. Cawthorne (2005). Prolonged treatment of genetically obese mice with conjugated linoleic acid (CLA) improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Obes. Rev. 6, Suppl. 1, 43, Abs. T2: O103.
J.R. Arch, D. Hislop, S.J. Wang and J. Speakman (2005). Some mathematical and technical issues in open-circuit indirect calorimetry. Physiol. Res. 54(2), 9P.
S. Narayanan, A. Thomas, D. Shah, B. Gopalan, S. Vakkalanka and J. Arch (2004). A novel, orally active dipeptidyl peptidase IV inhibitor potently improves glucose tolerance in mice. Diabetologia 47, Suppl. 1, A285, Abs. 788.
R.A. Ngala, S. Wang, J. O’Dowd, M.A. Cawthorne and J.R.S. Arch (2004). Atypical pharmacology and opposing effects of β-adrenoceptor agonists on glucose uptake in C2C12 cells: similarity with mouse soleus muscle pharmacology. Fundam. Clin. Pharmacol . 18, Suppl. 1, 36, Abs. P 04.22.
J.R.S. Arch (2004). β3-adrenoceptor agonists in obesity and type 2 diabetes: humans vs. rodents. Fundam. Clin. Pharmacol. 18, Suppl. 1, 11, Abs. S 09.2.
K. Smith, E. Wargent, A. Morrison, E. Grau, D. Smart, M. Cawthorne and J.Arch (2004). Normal suppression of feeding by leptin, but enhanced response to CB-1 receptor antagonists in BRS-3 knockout mice. Int. J. Obes. 28, Suppl. 1, S110, Abs. T3:P3-024.
S.J.Y. Wang and J. Arch, (2004). Reduced insulin sensitivity and glucose tolerance in DGAT-1 knockout mice. Int. J. Obes. 28, Suppl. 1, S90, Abs. T2:P2a-058.
N. Degabriele, S. Colombo, A. Medhurst, D. Sunter, J. Mercer and J. Arch, (2004). Insensitivity to tetrahydrocannabinol in rats sensitive to diet-induced obesity. Int. J. Obes. 28, Suppl. 1, S47, Abs. T7d:O1-006.
K. Smith; A. Haynes; H. Chapman, D. Smart and J.R.S. Arch (2004). Central administration of a bombesin receptor-2 agonist abolishes the anorexic effect of bombesin in refed rats Br. Pharmacol. Soc. Pa2 online Vol 2(1), Abs. 029P.
R. A. Ngala; S.J.Y. Wang, M. A. Cawthorne and J. R.S. Arch (2004). Biphasic and atypical pharmacology of glucose uptake in mouse isolated soleus muscle is dependent on the β2-adrenoceptor Br. Pharmacol. Soc. Pa2 online Vol 2(1), Abs. 008P.S. Wang, M.A. Cawthorne, J.R.S. Arch and J.C. Clapham (2003). Increased adiposity and low leptin in transgenic mice overexpressing UCP-3 in skeletal muscle after long term high fat feeding. Obes. Res. 11(9), Suppl, A30, Abs. 122-OR.
R. Ngala, S. Wang, M.A. Cawthorne and J.R.S. Arch (2003). Atypical pharmacology and opposing effects of β-adrenoceptor agonists on glucose uptake and pyruvate oxidation in skeletal muscle. Diabetologia 46, Suppl. 2, A210, Abs. 606.
G. Schmid, V. Converset, N. Walter, M. Sennitt, M. Ward, M. Cawthorne and J.-C. Sanchez (2003). Effect of high fat diet on the expression of proteins in muscle, adipose tissues and liver of C57Bl/6 mice. Diabetologia 46, Suppl. 2, A207, Abs. 596.
E.T. Wargent, M.V. Sennitt, C.-W. Woon and M.A. Cawthorne (2003). The DPPIV resistant GLP-1 analogue, BIM 51077, improves diabetic control in ZDF rats. Diabetologia 46, Suppl. 2, A169, Abs. 482.
C. Stocker, N.M. Morton, E. Wargent, J. O'Dowd, M.V. Sennitt, D. Hislop, J. Seckl, J.R.S. Arch and M.A. Cawthorne (2003). Leptin administration prevents reduction of placental 11β-hydroxysteroid dehydrogenase-2 associated with maternal protein restriction and prevents obesity in male offspring in a rat model of in utero growth retardation. Pediatr. Res. 53 (6), Suppl., p. 41A, Abs. P.628.
C. Stocker, E. Wargent, J. O'Dowd, M.V. Sennitt, D. Hislop, J.R.S. Arch and M.A. Cawthorne (2003). Maternal leptin administration attenuates high fat diet-induced insulin resistance in female offspring in a rodent model of in utero growth restriction without affecting adiponectin. Pediatr. Res. 53 (6), Suppl., p. 29A, Abs. P.337.
K. Smith, A. Medhurst, C. Stocker, D. Smart and J. Arch (2003). Expression of mRNA for bombesin receptors in hypothalami of fa/fa and fasted rats. Int. J. Obesity 27, Suppl. 1, S65, Abs. P1-091.
C. Stocker, E. Wargent, M.V. Sennitt, J. O'Dowd, D. Hislop, J.R.S. Arch and M.A. Cawthorne (2002). Administration of leptin to pregnant rats fed on a low protein diet prevents high fat diet induced insulin resistance in male offspring. Diabetes 51, Suppl 2, A144, Abs. 582-P.
S. Wang, A. Subramaniam, M.A. Cawthorne and J.C. Clapham (2001). Substrate oxidation in mice over-expressing human UCP-3 in skeletal muscle. Obesity Research 9, Suppl. 3, 113S, Abs. PB28.
C. Stocker, E. Wargent, M. Sennitt, A. Nolan, J. O'Dowd, K. Subramaniam, S. Wang and M. Cawthorne (2001). Maternal leptin administration induces resistance to diet-induced obesity of early growth restricted rats. Diabetologia 44, Suppl 1, A167, Abs 641.
A. Subramaniam, C. Stocker, M.V. Sennitt, S. Wang, A.L. Nolan, L. Brown, M. Bertrand, A. Peilow, A. Mayes and M.A. Cawthorne (2001). Guggul lipid reduces insulin resistance and body weight gain in C57Bl/6 lep/lep mice. Int. J. Obesity 25, Suppl. 2, S24, Abs. O66.
V. Emilsson, J. O'Dowd, A.L. Pallett and M.A. Cawthorne (2001). Hexosamine and nutrient excess induce leptin production and leptin receptor activation in islet b cells. Diabetes 50, Suppl. 2, A343, Abs. 1428.
C. Stocker, E. Wargent, A. Subramaniam, H-U. Demuth, M. Sennitt and M.A. Cawthorne (2001). The dipeptidyl peptidase inhibitor P32/98 improves glucose tolerance in diabetic ZDF rats. Diabetes 50, Suppl. 2, A522, Abs. 2200.
J.-C. Sanchez, D. Chiappe, M.V. Sennitt, V. Rouge, S. Wang, A.L. Pallett, D. Hochstrasser and M. Cawthorne (2000). Effects of the insulin sensitiser drug, rosiglitazone, on the differential expression of obesity-associated liver cytosolic and nuclear proteins of lep/lep mice. Obesity Research 8, Suppl. 1, 125S, Abs. PF38.
M.A. Cawthorne, K. Clavurier, C. Stocker, E. Whittle, A. Subramaniam, I. Rubin and M.V. Sennitt (2000). P57, a plant derived anorexic agent, reduces food intake and normalises blood glucose in ZDF rats. Obesity Research 8, Suppl. 1, 81S. Abs. PB55.
E. Wargent, A.L. Nolan, Y. Shen, J. Dong, J.E. Taylor, M. Culler, B. Morgan, C-W. Woon and M.A. Cawthorne (2000). Insulin secretagogue activity in vitro and in perfused pancreas of dipeptidase IV resistant GLP-1 analogues. Diabetologia 43, Suppl 1, A137, Abs 532.
A.L. Nolan, M.V. Sennitt, E.B. Whittle, C.J. Stocker and M.A. Cawthorne (2000). Acute and chronic effects of exendin-4 on glycaemic control and food intake in diabetic mice. Diabetologia 43, Suppl 1, A148, Abs 572.
M. Board, F. Preitner, J-P. Giacobino and M.A. Cawthorne (2000). The b3 -adrenoceptor agonist, BRL 37344, increases pyruvate and palmitate oxidation in soleus muscle of b3 -KO mice. Int. J. Obesity 24, Suppl 1, Abs 80, S30.
A.C. Haynes, B. Jackson, M.A. Cawthorne, S. Wilson, M. Tadayyon and J.R.S. Arch (2000). Interactions of the orexins and melanin concentrating hormone on feeding. Int. J. Obesity 24, Suppl 1, Abs 101, S37.
J-C. Sanchez, V. Rouge, D. Hochstrasser, M.V. Sennitt, S. Wang, A.L. Pallett and M.A. Cawthorne (2000). Effect of rosiglitazone on the differential expression of diabetes associated proteins in pancreatic islets of C57BI/6J lep/lep mice. Diabetes 49, Suppl 1, Abs 1041-P, A250.
M. Board, P. Doyle and M.A. Cawthorne (1999). Stimulation of oxidative metabolism of isolated skeletal muscle by b3-adrenoceptor (b3-AR) agonists: evidence for the existence of a novel b-AR in murine soleus muscle. Diabetes 48, Suppl 1, Abs 1991.
V. Emilsson, J. O'Dowd, S. Wang, R. Heyman and M. Cawthorne (1999). Effects of rexinoids and thiazolidinedione on levels of UCP isoforms and PGC-1 in the obese Zucker rat. Diabetologia 42, Suppl 1, A 206, Abs 774.
S.A. Smith, D. Boam, M.A. Cawthorne, J. Sidaway, M. Newman, M. Wilkinson, S. Dunmore, C.A. Lister (1998). Rosiglitazone reduces overexpression of insulin and amylin mRNA in hypertrophied pancreatic islets. Diabetologia 41, Suppl 1, A169, abs 659.
C.A.Lister, D. Boam, D. Bretherton-Watt, M.A. Cawthorne, G. Moore, S. Loughborough, J. Warrack, M. Wilkinson and S.A. Smith (1998). Rosiglitazone increases pancreatic islet cell area, number and insulin content, but not insulin gene expression. Diabetologia 41, Suppl 1, A169, abs 660.
A.L. Pallett, V. Emilsson, D. Coy, J. Taylor, C.-W. Woon and M.A. Cawthorne (1998). Reduced expression of somatostatin receptor sub-types in Zucker rat islets and functional typing of the somatostatin induced inhibition of insulin secretion. Diabetologia 41, Suppl 1, A152, abs 592.
V. Emilsson, J. Arch, R.P. De Groot, A.M. Kanu, Y-L. Liu, N.M. Morton, A.L. Pallett, C.A. Lister and M.A. Cawthorne (1998). A role for suppressors of leptin signalling in the states of leptin resistance. Presented at Symposium on Genetic and Molecular Basis of Obesity, Paris, 26-28 August 1998.
V. Emilsson, R.J. Summers, Y-L. Liu, A.M. Kanu, M.A. Cawthorne (1998). The effect of the b3-adrenoceptor agonist BRL 35135 on UCP-2 and UCP-3 mRNA levels in vivo. Presented at Symposium on Genetic and Molecular Basis of Obesity, Paris, 26-28 August 1998.
M.A. Cawthorne (1998). Thiazolidinediones in the treatment of Insulin Resistance Syndrome. Int. J. Obesity 22, Suppl 3, S86, abs O314.
M.A. Cawthorne, P.D. Chamberlain, K.H. Jennings, F. Paul, J. Cordell, A. Berry, S.D. Holmes, J. Park, J. Chambers, M.V. Sennitt, M.J. Stock, P.W. Young and G.J. Murphy (1998). Direct evidence of a b3-adrenoceptor expression in human adipose tissue, atrium and skeletal muscle obtained using a novel monoclonal antibody. Int. J. Obesity 22, Suppl 3, S74, abs O267.
M. Board and M.A. Cawthorne (1998). Abnormal response of glucose uptake by soleus muscle from ob/ob mice to BRL 37344. Int. J. Obesity 22, Suppl 3, S189, abs P355.
Y.-L. Liu, M.V. Sennitt, D.C. Hislop, D.L. Crombie, R.A. Heyman and M.A. Cawthorne (1998). Rexinoid X receptor agonists improve insulin sensitivity and have anti-obesity effects in Zucker fa/fa rats. Diabetes 47, Suppl 1, A283, abs 1099.
S.A. Smith, D. Boam, M.A. Cawthorne, J. Sidaway, M. Newman, M. Wilkinson, S. Dunmore, and C.A. Lister (1998). Rosiglitazone improves insulin sensitivity and reduces hyper-expression of insulin and amylin mRNAs in pancreatic islets. Diabetes 47, Suppl 1, A94. abs 0365.
S.A. Smith, D. Boam, D. Bretherton-Watt, M.A. Cawthorne, G. Moore, S. Loughborough, J. Warrack, M. Wilkinson and C.A.Lister (1998). Rosiglitazone increases pancreatic islet cell area, density and insulin content, but not insulin gene expression. Diabetes 47, Suppl 1, A18, abs 0072.
N.M. Morton, V. Emilsson, A.L. Pallett and M.A. Cawthorne (1998). Leptin signalling in pancreatic beta cells. British Diabetic Association, Edinburgh.
N.M. Morton, V. Emilsson and M.A. Cawthorne (1998). Interleukin 1b induces a novel STAT-DNA binding activity in the insulin secreting cell line Rin m5F. Keystone symposium on JAK and STAT signalling.
N.M. Morton, V. Emilsson, A.L. Pallett and M.A. Cawthorne (1997). Leptin-induced tyrosine phosphorylation in islets from ob/ob mice. Exp. Clin. Endocrinol. Diabetes 105, 4, A35.
A.L. Pallett, N.M. Morton, V. Emilsson and M.A. Cawthorne (1997). Effect of leptin on glucose stimulated insulin secretion in isolated rat islets. Exp. Clin. Endocrinol. Diabetes 105, 4, A41.
S. Pearson, M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B.T. Moore, S.A. Smith and Tadayyon, M. (1997). The insulin sensitiser, BRL 49653, increases expression of PPAR-g and aP2 mRNA but does not effect UCP or b3-AR mRNA. Int. J. Obesity 21, Suppl 2, 180, S61.
V. Emilsson, N. Cheung, M.V. Sennitt and M.A. Cawthorne (1997). Melanin concentrating hormone stimulates leptin secretion from adipocytes. Diabetologia 40, Suppl 1, 678, A173.
Y.L. Liu, V. Emilsson, and M.A. Cawthorne (1997). Inhibition of glycogen synthesis by leptin in isolated soleus muscle of obese (ob/ob) mice. Int. J. Obesity 21, Suppl 2, 23, S13.
M.A. Cawthorne, Y.L. Liu, Morton, N., Davenport, M. and Emilsson, V. (1997). Is there a role for leptin in the development of NIDDM? Diabetic Med.
Book Chapters, Specialist Report and Review
Stocker CJ (ed.). Type 2 Diabetes: Methods and Protocols (London: Humana Press, 2009).
Read more about this book in our Publication of the week section (14 September 2009)
O'Dowd J. The isolation and purification of rodent pancreatic islets of Langerhans. In: Type 2 Diabetes: Methods and Protocols (London: Humana Press, 2009), ed. Stocker, C., pp37–42. doi:10.1007/978-1-59745-448-3_3
Nolan AL, O'Dowd J. The measurement of insulin secretion from isolated rodent islets of Langerhans. In: Type 2 Diabetes: Methods and Protocols (London: Humana Press, 2009), ed. Stocker, C., pp43–51. doi:10.1007/978-1-59745-448-3_4
Wargent ET. The measurement of insulin secretion using pancreas perfusion in the rodent. In: Type 2 Diabetes: Methods and Protocols (London: Humana Press, 2009), ed. Stocker, C., pp203–219. doi:10.1007/978-1-59745-448-3_14
Arch JRS. How might regulators’ expectations of novel anti-obesity drugs be achieved? The Diabetes Report. 2008 Jan: pp1–4.
Arch JRS. Thermogenesis and related targets for anti-obesity drugs. In: Obesity and Metabolic Disorders (Amsterdam: IOS Press, 2005), ed. Antel J., Finer N, Heal D and Krause G., pp143–160.
Cawthorne MA. Promising new targets for the next generation of anti-obesity drugs. In: Obesity and Metabolic Disorders (Amsterdam: IOS Press, 2005), ed. Antel J., Finer N, Heal D and Krause G., pp201–214.
Cawthorne MA, Heald M. Leptin (Amgen). Curr. Opin. Oncol. Endocrine Metabol. Invest. Drugs 2000 2: pp217–226.